Despite Reductions In NHI Prices Kyowa Hakko Kirin Reports Strong Pharma Sales, Revises Full Year Forecast
This article was originally published in PharmAsia News
Executive Summary
Despite National Health Insurance reimbursement price reductions, major drug maker Kyowa Hakko Kirin still saw a 52 percent increase in pharmaceutical sales and a 71 percent rise in operating income, which the company attributed to the synergy of the newly merged company during a third-quarter earnings call Jan 30
You may also be interested in...
Newly Merged Japanese Firm Files For First Drug Approval In China
Japan's Kyowa Hakko Kirin applied for approval of its allergy drug in China as part of an effort to expand business there. Kyowa Hakko Kogyo and Kirin Pharma merged in October as a way for the former company to enlarge is presence in China. The first drug the new firm seeks to market is Allelock (olopatadine) antihistamine. Since the drug already is approved in Japan, under Chinese rules Allelock needs to undergo only a Phase III trial, enabling it to reach the Chinese market in 2010. (Click here for more - a subscription may be required
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).